Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of alobresib (GS-5829) in adults with advanced solid tumors and lymphomas,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Estrogen Receptor-positive Breast Cancer
• Lymphomas
• Solid Tumors

Drugs mentioned

• Exemestane (Exemestane)
• Fulvestrant (fulvestrant)
• alobresib (alobresib)

Snippet

Sponsor: Gilead Sciences | Conditions: Solid Tumors and Lymphomas | Phase 1 | Status: COMPLETED | Results posted: 2020-12-29